Notice: This company has been marked as potentially delisted and may not be actively trading. GTX (GTXI) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends GTXI vs. FBIO, SABS, CRIS, BOLT, MTEM, AMGN, GILD, VRTX, REGN, and ALNYShould you be buying GTX stock or one of its competitors? The main competitors of GTX include Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), Curis (CRIS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Alnylam Pharmaceuticals (ALNY). These companies are all part of the "biotechnology" industry. GTX vs. Fortress Biotech SAB Biotherapeutics Curis Bolt Biotherapeutics Molecular Templates Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Fortress Biotech (NASDAQ:FBIO) and GTX (NASDAQ:GTXI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation. Does the media favor FBIO or GTXI? In the previous week, GTX had 1 more articles in the media than Fortress Biotech. MarketBeat recorded 5 mentions for GTX and 4 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 0.18 beat GTX's score of 0.00 indicating that Fortress Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GTX 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of FBIO or GTXI? 96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 9.5% of GTX shares are owned by institutional investors. 33.4% of Fortress Biotech shares are owned by company insiders. Comparatively, 40.9% of GTX shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more volatility & risk, FBIO or GTXI? Fortress Biotech has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500. Comparatively, GTX has a beta of 2.22, meaning that its stock price is 122% more volatile than the S&P 500. Do analysts prefer FBIO or GTXI? Fortress Biotech currently has a consensus price target of $13.67, indicating a potential upside of 667.79%. Given Fortress Biotech's stronger consensus rating and higher possible upside, equities analysts clearly believe Fortress Biotech is more favorable than GTX.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fortress Biotech 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00GTX 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in FBIO or GTXI? Fortress Biotech received 12 more outperform votes than GTX when rated by MarketBeat users. However, 73.60% of users gave GTX an outperform vote while only 63.62% of users gave Fortress Biotech an outperform vote. CompanyUnderperformOutperformFortress BiotechOutperform Votes32763.62% Underperform Votes18736.38% GTXOutperform Votes31573.60% Underperform Votes11326.40% Is FBIO or GTXI more profitable? GTX has a net margin of 0.00% compared to Fortress Biotech's net margin of -84.53%. Fortress Biotech's return on equity of 0.00% beat GTX's return on equity.Company Net Margins Return on Equity Return on Assets Fortress Biotech-84.53% N/A -34.93% GTX N/A -104.19%-86.42% Which has higher earnings and valuation, FBIO or GTXI? GTX has lower revenue, but higher earnings than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than GTX, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFortress Biotech$84.51M0.58-$60.64M-$3.05-0.58GTXN/AN/A-$38.42M-$1.65-0.32 SummaryFortress Biotech beats GTX on 9 of the 17 factors compared between the two stocks. Get GTX News Delivered to You Automatically Sign up to receive the latest news and ratings for GTXI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GTXI vs. The Competition Export to ExcelMetricGTXPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.67M$6.92B$5.62B$9.14BDividend YieldN/A2.95%5.36%3.98%P/E Ratio-0.3210.1189.6917.66Price / SalesN/A351.361,219.4081.09Price / CashN/A65.4844.3437.71Price / Book0.485.335.134.73Net Income-$38.42M$157.56M$118.85M$225.42M GTX Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GTXIGTXN/A$0.53flatN/AN/A$12.67MN/A-0.3221FBIOFortress Biotech2.5034 of 5 stars$1.80-1.1%$13.67+659.3%-17.1%$49.68M$84.51M-0.59170Short Interest ↑SABSSAB Biotherapeutics3.2238 of 5 stars$4.36+6.3%$12.40+184.4%-62.8%$40.24M$2.24M0.00140Analyst ForecastShort Interest ↓News CoverageHigh Trading VolumeCRISCuris2.784 of 5 stars$3.17-7.3%$23.00+625.6%-66.2%$26.85M$10.02M-0.4160Short Interest ↑BOLTBolt Biotherapeutics3.3984 of 5 stars$0.51+0.6%$3.50+581.9%-54.7%$19.64M$7.88M-0.3090Short Interest ↑News CoverageGap UpMTEMMolecular TemplatesN/A$0.00+200.0%N/A-100.0%$2,000.00$57.31M0.00260Gap UpAMGNAmgen4.8706 of 5 stars$282.95+2.7%$314.65+11.2%-10.1%$152.09B$28.19B36.2326,700Upcoming EarningsAnalyst ForecastPositive NewsGILDGilead Sciences4.763 of 5 stars$95.35+2.4%$97.96+2.7%+20.9%$118.83B$27.12B1,059.4418,000Analyst ForecastShort Interest ↑News CoveragePositive NewsVRTXVertex Pharmaceuticals4.2191 of 5 stars$443.88+1.0%$494.76+11.5%+1.3%$114.31B$9.87B-223.065,400Analyst ForecastAnalyst RevisionNews CoverageREGNRegeneron Pharmaceuticals4.7292 of 5 stars$684.71+1.3%$1,006.71+47.0%-28.1%$75.24B$13.12B16.9413,450Analyst ForecastAnalyst RevisionALNYAlnylam Pharmaceuticals4.0724 of 5 stars$276.73-0.7%$298.61+7.9%+51.4%$35.69B$1.83B-105.622,100Insider TradeAnalyst RevisionNews Coverage Related Companies and Tools Related Companies Fortress Biotech Competitors SAB Biotherapeutics Competitors Curis Competitors Bolt Biotherapeutics Competitors Molecular Templates Competitors Amgen Competitors Gilead Sciences Competitors Vertex Pharmaceuticals Competitors Regeneron Pharmaceuticals Competitors Alnylam Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GTXI) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredTrump’s back in the oval office. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. And he says 2025 could be...Weiss Ratings | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GTx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GTX With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
